<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>antibody durability &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/antibody-durability/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Fri, 16 Oct 2026 06:55:17 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>antibody durability &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Longer Gap Between Doses Boosts Durability of Self-Amplifying mRNA H5N1 Flu Vaccine in Phase 1 Trial</title>
		<link>https://bioengineer.org/longer-gap-between-doses-boosts-durability-of-self-amplifying-mrna-h5n1-flu-vaccine-in-phase-1-trial/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Fri, 16 Oct 2026 06:55:17 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[antibody durability]]></category>
		<category><![CDATA[ARCT-2304]]></category>
		<category><![CDATA[Arcturus Therapeutics]]></category>
		<category><![CDATA[BARDA]]></category>
		<category><![CDATA[dose interval]]></category>
		<category><![CDATA[H5N1 influenza]]></category>
		<category><![CDATA[hemagglutinin]]></category>
		<category><![CDATA[neuraminidase]]></category>
		<category><![CDATA[Pandemic Preparedness]]></category>
		<category><![CDATA[Phase 1 trial]]></category>
		<category><![CDATA[self-amplifying mRNA]]></category>
		<category><![CDATA[vaccine immunogenicity]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=421949</guid>

					<description><![CDATA[A Phase 1 trial found that an eight-week dosing interval produced stronger and longer-lasting antibody responses against H5N1 influenza than a four-week interval for the self-amplifying mRNA vaccine ARCT-2304.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">421949</post-id>	</item>
	</channel>
</rss>
